Binge Eating Disorder Clinical Trial
Official title:
Appetite Hormones in Binge Eating Disorder
This study investigates the hormones that the body produces in response to food intake and in response to stress, and the way that stress influences food intake. In particular, it compares the hormone levels and food intake of people with and without binge eating disorder. In order to find out how these appetite- and stress-related hormones are linked to brain activity, the study also includes an fMRI scan, a non-invasive procedure that looks at which regions of the brain are most active during a food-related scenario.
Status | Completed |
Enrollment | 96 |
Est. completion date | January 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - BMI of 20-25 or 30-50 - stable weight(± 4%) for at least 3 mo - premenopausal and have regular menstrual cycles (28 d ± 5), not be pregnant or lactating, and not be within 1 y of childbirth - must like pizza and be willing to consume it during the ad libitum meal Exclusion Criteria: - significant medical or psychiatric conditions - current and past 3-mo use of certain prescribed medications, especially those that could affect body weight, such as antidepressants and stimulants as well as smoking, or excess alcohol (> 3 drinks/d) - vigorously exercise for more than 6 h/wk - left-handed, with known claustrophobia for a scanner enclosure, or have metal implants, non-removable metallic dental retainers, pacemakers, or permanent eyeliner or large tattoos that contain metallic pigment |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Luke's Hospital | New York | New York |
Lead Sponsor | Collaborator |
---|---|
New York Obesity and Nutrition Research Center | Columbia University, St. Luke's-Roosevelt Hospital Center |
United States,
Anderson DA, Williamson DA, Johnson WG, Grieve CO. Validity of test meals for determining binge eating. Eat Behav. 2001 Summer;2(2):105-12. — View Citation
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003 Sep 4;349(10):941-8. — View Citation
Castonguay TW. Glucocorticoids as modulators in the control of feeding. Brain Res Bull. 1991 Sep-Oct;27(3-4):423-8. — View Citation
Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003 Feb 20;37(4):649-61. — View Citation
de Zwaan M, Mitchell JE, Raymond NC, Spitzer RL. Binge eating disorder: clinical features and treatment of a new diagnosis. Harv Rev Psychiatry. 1994 Mar-Apr;1(6):310-25. Review. — View Citation
English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002 Jun;87(6):2984. — View Citation
Epel E, Lapidus R, McEwen B, Brownell K. Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. Psychoneuroendocrinology. 2001 Jan;26(1):37-49. — View Citation
Geliebter A, Gluck ME, Hashim SA. Plasma ghrelin concentrations are lower in binge-eating disorder. J Nutr. 2005 May;135(5):1326-30. — View Citation
Geliebter A, Hassid G, Hashim SA. Test meal intake in obese binge eaters in relation to mood and gender. Int J Eat Disord. 2001 May;29(4):488-94. — View Citation
Geliebter A, Ladell T, Logan M, Schneider T, Sharafi M, Hirsch J. Responsivity to food stimuli in obese and lean binge eaters using functional MRI. Appetite. 2006 Jan;46(1):31-5. Epub 2005 Dec 20. Erratum in: Appetite. 2006 May;46(3):395. Schweider, Tzipporah [corrected to Schneider, Tzipporah]. — View Citation
Geliebter A, Melton PM, McCray RS, Gallagher DR, Gage D, Hashim SA. Gastric capacity, gastric emptying, and test-meal intake in normal and bulimic women. Am J Clin Nutr. 1992 Oct;56(4):656-61. — View Citation
Geliebter A, Yahav EK, Gluck ME, Hashim SA. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav. 2004 Jul;81(5):735-40. — View Citation
Gluck ME, Geliebter A, Hung J, Yahav E. Cortisol, hunger, and desire to binge eat following a cold stress test in obese women with binge eating disorder. Psychosom Med. 2004 Nov-Dec;66(6):876-81. — View Citation
Hellström PM, Geliebter A, Näslund E, Schmidt PT, Yahav EK, Hashim SA, Yeomans MR. Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr. 2004 Aug;92 Suppl 1:S47-57. Review. — View Citation
Kelly CB, Cooper SJ. Plasma norepinephrine response to a cold pressor test in subtypes of depressive illness. Psychiatry Res. 1998 Oct 19;81(1):39-50. — View Citation
Koo-Loeb JH, Costello N, Light KC, Girdler SS. Women with eating disorder tendencies display altered cardiovascular, neuroendocrine, and psychosocial profiles. Psychosom Med. 2000 Jul-Aug;62(4):539-48. — View Citation
Monteleone P, Martiadis V, Fabrazzo M, Serritella C, Maj M. Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. Psychol Med. 2003 Nov;33(8):1387-94. — View Citation
Monteleone P, Martiadis V, Rigamonti AE, Fabrazzo M, Giordani C, Muller EE, Maj M. Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. Biol Psychiatry. 2005 Apr 15;57(8):926-31. — View Citation
Raymond NC, Neumeyer B, Warren CS, Lee SS, Peterson CB. Energy intake patterns in obese women with binge eating disorder. Obes Res. 2003 Jul;11(7):869-79. — View Citation
Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996 Aug;271(2 Pt 1):E317-25. — View Citation
Walsh BT, Boudreau G. Laboratory studies of binge eating disorder. Int J Eat Disord. 2003;34 Suppl:S30-8. Review. — View Citation
Yanovski SZ. Binge eating disorder: current knowledge and future directions. Obes Res. 1993 Jul;1(4):306-24. Review. — View Citation
* Note: There are 22 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Appetite-related Hormones and Appetite Ratings in Relation to Fixed Meal and Cold Pressor Test | Blood and saliva concentrations of hormones influencing appetite will be measured at systematic intervals (-15, 0, 10, 30, 60, 90, 120 min) before and after the morning fixed meal at 10.00 and the evening fixed meal at 17.00. Appetite will additionally be rated at each assessment point. This will be followed by a cold pressor test, and then 30 min later by an ad libitum meal 30 min later, with blood and saliva measurements taken before and after completion of the meal. | Assessed at systematic intervals (-15, 0, 10, 30, 60, 90, 120 min) before and after the morning fixed meal at 10.00 and the evening fixed meal at 17.00 | No |
Secondary | Cortisol Awakening response | On one weekday morning during the 3-week participation period, participants will take one saliva measurement on awakening and at 08.00 while still fasting. Awakening and 08.00 cortisol levels are expected to be higher in BED compared with nonBED Ss, and in obese nonBED compared with normal-weight nonBED Ss. | Assessed on one weekday morning during the 3-week participation period | No |
Secondary | Psychological Scales | Various questionnaires will be administered to test relationships between outcomes (e.g., intake, hormone levels), and psychological constructs including depression, perceived stress, external and emotional eating and restraint, binge-eating behavior, and night eating. Outcomes will be correlated with scale scores, and scores will be compared between groups. Among other relationships, we anticipate positive correlations between binge eating score, ad libitum intake and ghrelin SECPT response. Psychological scores will be entered as covariates as appropriate. | During one initial consultation and on two subsequent visits at least 1 week apart | No |
Secondary | Body Weight, Body Composition and Gender | Measurements will include height, weight, waist circumference, total body fat from BIA, and cross-sectional abdominal MRI to estimate central, visceral, and subcutaneous fat. Each adiposity index will be correlated with outcomes and compared between groups. | During one initial consultation and on two subsequent visits at least 1 week apart | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 | |
Completed |
NCT00032760 -
Meditation-Based Treatment for Binge Eating Disorder
|
Phase 2/Phase 3 |